Risk-Adjusted Length of Stay >14 Days after Elective Lobectomy for Lung Cancer
Description
Percentage of patients aged 18 years and order undergoing elective lobectomy for lung cancer who had a prolonged length of stay >14 days
Percentage of patients aged 18 years and order undergoing elective lobectomy for lung cancer who had a prolonged length of stay >14 days
Percentage of patients aged 18 years and older undergoing elective esophagectomy for esophageal cancer who developed any of the following postoperative conditions: bleeding requiring reoperation, anastomosis leak requiring medical or surgical treatment, reintubation, ventilation >48 hours, pneumonia, or discharge mortality
Percentage of patients greater than or equal to 18 years of age undergoing elective lung resection (Open or VATS wedge resection, segmentectomy, lobectomy, bilobectomy, sleeve lobectomy, pneumonectomy) for lung cancer who developed any of the following postoperative complications: reintubation, need for tracheostomy, initial ventilator support > 48 hours, ARDS, pneumonia, pulmonary embolus, bronchopleural fistula, unexpected return to the operating room, myocardial infarction or operative mortality (death during the index hospitalization, regardless of timing, or within 30 days, regardle
Percent of patients aged 18 years and older undergoing cardiac surgery who had an order for or received preoperative prophylactic antibiotics recommended for the operation.
Standardized average length of hospital stay (ALOS) for routine inpatient care (i.e., care provided outside of intensive care units).
Ratio of observed to expected major adverse events (MAE) among patients undergoing congenital cardiac catheterization, risk-adjusted using the Catheterization for Congenital Heart Disease Adjustment for Risk Method II (CHARM II).
This measure is a ratio of observed to expected rate of in-hospital mortality following non-cardiac surgery among infants <= 30 days of age, risk-adjusted.
Percent of acute myocardial infarction (AMI) patients who are prescribed a statin at hospital discharge.
This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day two (with the day of arrival being day 1).
This measure captures the proportion of ischemic or hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given on the day of or the day after hospital admission.